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Abstract 
Background: Older adults are reported to have sub-optimal B vitamin status; targeted food-based solutions may 
help to address this. The objectives of the OptiAge food intervention study were to develop and investigate the effec-
tiveness of a B vitamin-fortified drink in improving B vitamin biomarkers in older Irish adults with a primary outcome 
of change in the B vitamin biomarker status.
Methods: A double-blinded randomised controlled trial was performed in parallel at University College Dublin and 
Ulster University. Participants aged > 50 years were recruited following screening for exclusion criteria (i.e. taking medi-
cations known to interfere with B vitamin metabolism, supplements containing B vitamins, consuming > 4 portions of 
B vitamin-fortified foods per week or diagnosed with gastrointestinal, liver or pulmonary disease). Recruited partici-
pants meeting the inclusion criteria were randomised (by sex and study centre) to receive daily for 16 weeks either B 
vitamin-fortified or placebo drinks as developed by Smartfish, Norway. Each B vitamin-fortified drink (200 ml) con-
tained 200 µg folic acid, 10 µg vitamin B12, 10 mg vitamin B6 and 5 mg riboflavin, while the placebo was an identical, 
isocaloric formulation without added B vitamins. Fasting blood samples were collected pre- and post-intervention 
which were used to measure the primary outcome of change in B vitamin biomarker levels.
Results: A total of 95 participants were randomised, of which 81 commenced the trial. Of these, 70 completed (37 in 
the active and 33 in the placebo groups). Intention to treat (ITT) analysis of the B vitamins demonstrated a significant 
improvement in all B vitamin biomarkers in the active compared to placebo groups: p < 0.01 for each of serum folate, 
serum vitamin B12 and plasma pyridoxal 5′-phosphate (vitamin B6) and the functional riboflavin biomarker, eryth-
rocyte glutathione reductase activation coefficient (EGRac). Correspondingly, a significant lowering of serum homo-
cysteine from 11.9 (10.3–15.1) µmol/L to 10.6 (9.4–13.0) µmol/L was observed in response to the active treatment 
(P < 0.001). Similar results were seen in a per-protocol analysis.
Conclusions: The results demonstrate that a B vitamin-fortified drink was effective in optimising B vitamin status, 
making this a useful intervention option to improve B vitamin status in older adults.
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Background
One-carbon metabolism is a series of interlinking meta-
bolic pathways that provides one-carbon units for the 
synthesis of DNA, amino acids and phospholipids. The 
B-vitamins folate, vitamin B12, vitamin B6, and ribofla-
vin are central to the functioning of one-carbon metabo-
lism. A high proportion of older Irish adults are reported 
to have sub-optimal B vitamin status. Findings from the 
most recent National Adult Nutrition Survey (NANS) 
indicated that > 50% of older adults have riboflavin sta-
tus considered to be low/deficient (EGRac (erythrocyte 
glutathione reductase activation coefficient) > 1.3), while 
approximately 20% have insufficient intakes of riboflavin 
[13]. Results from the Irish Longitudinal Study on Ageing 
(TILDA) have additionally indicated that 12% and 15% 
of older adults have low vitamin B12 and folate status, 
respectively [16]. Furthermore, the prevalence of insuffi-
cient folate and vitamin B12 status is much higher among 
non-consumers of fortified foods, predominantly break-
fast cereals and fat spreads, compared to regular consum-
ers [12]. Therefore, new strategies, including novel foods 
targeted at older people, are needed to improve B vitamin 
status.
Fortified drinks offer a potential route for enhancing 
vitamin status, but relatively few studies have investi-
gated the potential of drinks fortified with B vitamins 
to improve B vitamin biomarker status. The majority of 
previous studies that investigated the effect of fortified 
drinks on status were performed in children and have 
generally included multiple vitamins and minerals to 
improve nutritional status in geographical areas where 
micronutrient deficiencies are common [2, 3, 28]. In one 
such study, children in India received daily a drink forti-
fied with 0.63 mg riboflavin, 35 µg folic acid and 1.27 µg 
vitamin B12 for 8  weeks [28], resulting in significant 
improvements in blood concentrations of folate and vita-
min B12. Other studies that administered fortified drinks 
in children focussed on iron supplementation for preven-
tion of anaemia [2, 3]. A limited number of studies have 
investigated the effect of intervention using B vitamin-
fortified drinks in older adults. In one such interven-
tion study using a drink enriched with multiple minerals 
and vitamins which included 1.9 mg vitamin B2, 2.5 mg 
vitamin B6, 480 µg folic acid and 5.3 µg vitamin B12 was 
administered to frail institutionalised elderly people [29]. 
Following 6 months of daily consumption of the drinks, 
plasma B12 increased while plasma homocysteine signifi-
cantly decreased; correspondingly, cognition improved 
as assessed by scores in the Word Learning test and 
Category Fluency tests in the group that received the 
enriched drinks. No results for folate, vitamin B6 or ribo-
flavin biomarkers were reported. A second study used 
the same multinutrient drink in a larger cohort to inves-
tigate the effects of these vitamins on both mental and 
physical function [20]. Again, the enriched drinks were 
effective in decreasing homocysteine concentrations and 
increasing serum vitamin B12, along with vitamin B6 and 
folate concentrations, but results for riboflavin were not 
reported. Overall, these studies highlight the potential 
of drinks fortified in B vitamins as a practical means of 
enhancing B vitamin status in older adults. Therefore, the 
objective of this research was to investigate the effective-
ness of a novel drink product, fortified with folic acid, 
vitamin B12, vitamin B6 and riboflavin, in optimising B 
vitamin status in healthy older adults.
Materials and methods
Inclusion criteria and randomisation
The Opti-Age Food Intervention Study was a dual-cen-
tre study based in University College Dublin (UCD) and 
Ulster University, Coleraine (UU) and was approved at 
each centre by their respective ethics committees (UCD 
ethics number: LS-18-60-Brennan, UU: REC/18/0033). 
Free-living adults aged 50 years and over were recruited 
for this study. The sample size required for this study was 
estimated using plasma homocysteine as a functional 
indicator of B-vitamin adequacy and based on the signifi-
cant difference in plasma homocysteine concentrations 
(of 2.1  µmol/l) between high consumers and non-con-
sumers of B vitamin fortified foods, as determined from 
our previous study [11]. Using the online sample size 
calculator (SPH Analytics [26]), and mean (SD) homo-
cysteine values for non-consumers and high consumers 
of fortified food of 12.2 (3.9) and 10.1 (3.5), respectively, 
from our previous study [11], a sample size of 38 subjects 
per treatment group was estimated based on a power of 
80% (β) and a significance level (α) of 0.05. Note in our 
previous report, the homocysteine values were presented 
as median and and interquartile range [11], and there-
fore required conversion to mean (SD) for the purposes 
of applying the online sample size calculator in the cur-
rent study. Allowing for potential drop-outs, we aimed to 
recruit 45 participants per treatment group.
Participants were recruited through posters displayed 
around each university campus and surrounding areas, 
notices in local church newsletters, by oral presentation 
Trial registration ISRCTN, ISRCTN61709781—Retrospectively registered, https:// www. isrctn. com/ ISRCT N6170 9781
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to parents in a local primary school and contacting com-
munity groups. Interested individuals were provided 
with the participant information sheet and allowed 
time to consider taking part. Potential participants were 
screened for eligibility using a short interview for forti-
fied food and supplement consumption. Participants 
were included if they consumed four portions or less of 
fortified food per week and did not currently or had not 
in the previous 4  months consumed a supplement con-
taining B vitamins. Participants were excluded if they had 
a diagnosis of coeliac disease, Crohn’s disease, ulcerative 
colitis, liver disease (NAFLD and hepatitis) or chronic 
obstructive pulmonary disease or were taking medica-
tions known to interfere with B vitamin metabolism, or if 
they were taking part in other research or unable to give 
informed consent to take part. Additionally, women were 
excluded if they were taking hormone replacement ther-
apy, were pregnant or lactating.
The fortified drinks used in the intervention were man-
ufactured by Smartfish (Norway) and shipped to the two 
study centres where they were stored at room tempera-
ture until distributed. Each 200 ml drink was mixed fruit-
flavoured and manufactured to contain 200 µg folic acid, 
10 µg vitamin B12, 10 mg vitamin B6 and 5 mg riboflavin 
in the active version, while the placebo was an identical, 
isocaloric formulation which did not contain B vitamins. 
Both the intervention and placebo drinks contained 10 µg 
vitamin D. B vitamin content in the drinks were inde-
pendently analysed after manufacture and analysis was 
repeated during and post intervention. The drinks were 
provided in opaque cartons. The intervention was double 
blinded with an independent researcher at each centre 
responsible for packing the drinks into opaque bags for 
distribution. Eligible participants were randomised, with 
gender and centre as factors in the randomisation, by an 
independent researcher to receive either the B vitamin or 
placebo version of the drinks to consume once daily for 
16 weeks.
Data collection
Participants attended a study centre for data collection 
pre and post intervention. At each appointment, anthro-
pometric measurements (height, weight, waist and hip 
circumference) and blood pressure (following NICE 
guidelines) were measured by centrally trained research-
ers and a short previously used questionnaire on health, 
diet and lifestyle was administered [17, 23].
Blood pressure was measured using an Omron 705IT 
monitor. One measurement was taken initially from 
each arm. The arm from which the highest measure-
ment was obtained was then considered the reference 
arm. Measurements were then taken from the reference 
arm at 1-min intervals until two measurements which 
agreed to within 5 mmHg for both systolic and diastolic 
blood pressure were obtained, and the mean of these was 
calculated.
A fasting blood sample was also collected at each 
appointment into the following tubes: 1 × 8  ml serum, 
1 × 6  ml lithium heparin, 2 × 9  ml EDTA (one imme-
diately put on ice, the other kept at room temperature). 
Serum tubes were left to clot for 30  min prior to cen-
trifugation. Lithium heparin samples were centrifuged at 
1800×g for 10  min at 4  °C and aliquoted within 1  h of 
the sample being drawn. Serum and EDTA samples were 
centrifuged at 1628×g for 15 min at 4 °C and the super-
natant subsequently aliquoted. In EDTA tubes, the buffy 
coat was removed before the red blood cells were washed 
3 times with phosphate-buffered saline. After each cen-
trifugation, the saline was removed and washed red cells 
were aliquoted within a maximum of 4 h of sample draw. 
All aliquots were stored at − 80 °C until analysis. Serum 
samples were used to analyse for homocysteine and bio-
markers of vitamin D, vitamin B12 and folate. EDTA 
plasma samples were used to analyse vitamin B6 bio-
markers and EDTA washed red blood cells were used to 
analyse a biomarker of riboflavin status.
Delivery of the intervention and assessment of compliance
Prior to commencing the intervention, participants 
completed a 4-day food diary. This diary was examined 
by researchers and based on the contents, participants 
were advised of substitutions and alterations that could 
be made to their diet to account for the daily addition 
of the approximately 200  kcal drink. Participants were 
advised to reduce consumption of foods such as confec-
tionary, crisps, desserts, biscuits and chocolate, i.e. foods 
high in calories but with limited nutritional value. A 
dietary advice sheet was also provided to participants to 
refer to during the study. Participants generally received 
their drinks in 2–3 lots for ease of transport. Compliance 
was assessed using a checklist which participants were 
instructed to complete daily on consumption of a drink. 
In addition, any drinks not consumed by participants 
during the 16-week intervention period were collected 
and counted. Of the 70 participants who completed the 
study, 59 had compliance > 90%, a further 7 participants 
had compliance of 80–90%, while only one participant 
consumed < 80% of the drinks (compliance data was 
missing for n = 3 participants).
Biomarker analysis
Riboflavin status was determined at Ulster University 
using an erythrocyte glutathione reductase activation 
coefficient assay (EGRac) which measures the activity 
of the enzyme glutathione reductase before and after 
in  vitro reactivation with its prosthetic group FAD. 
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EGRac is calculated as the ratio of FAD-stimulated to 
unstimulated enzyme activity, with a value ≥ 1.30 gen-
erally indicative of suboptimal riboflavin status, while 
values ≥ 1.40 are considered to indicate riboflavin defi-
ciency. Plasma pyridoxal 5′-phosphate (PLP) concen-
tration served as a biomarker of vitamin B-6 status and 
was measured, also at ulster University, by reversed 
phase, high performance liquid chromatography with 
fluorescence detection [4]. Serum folate, vitamin B12 
and homocysteine were measured at Bevital Laboratory, 
Bergen, Norway (www. bevit al. no). Serum folate concen-
trations were measured by a microbiological assay based 
on a chloramphenicol-resistant strain of Lactobacillus 
casei [21]. Value below the WHO cut-off of 10  nmol/L 
were considered to indicate deficiency. Serum vitamin 
B12 was determined by microbiological assay using Lac-
tobacillus leichmanni, while homocysteine was measured 
by fluorescence polarisation assay. Serum vitamin B12 
concentrations below 150  pmol/L were considered defi-
cient, values of 150–221 pmol/L were indicative of insuf-
ficiency while values above 221 pmol/L were considered 
sufficient. For homocysteine, the recent consensus state-
ment on homocysteine and dementia cut-off was used, 
with values above 11 nmol/L indicating elevated homo-
cysteine. Serum vitamin D was measured on an API 4000 
AB Sciex liquid chromatography mass spectrometer (AB 
Sciex UK Limited, Warrington, UK) as 25-hydroxyvita-
min D (the recognised blood marker of vitamin D status). 
A proprietary assay method developed by Chromsys-
tems GmbH, Munich, Germany (MassChrom® 25-OH-
Vitamin D3/D2 in Serum/Plasma) was used and samples 
underwent a pre-assay extraction followed by further 
purification by high pressure liquid chromatography 
before injection into the mass spectrometer. Vitamin D 
biomarker analysis was conducted in St James’ Hospital, 
Dublin.
Statistical analysis
All biomarker data were inspected for extreme outli-
ers (> 2 standard deviations from the mean). One such 
outlier was identified for folate at the pre-intervention 
timepoint and was removed from the database. Imputa-
tion of this and other missing values was performed by 
a statistician using 3 different methods – Random For-
rest imputation, Bayesian linear regression imputation 
and Bayesian imputation with bootstrapping. The most 
appropriate method for each biomarker was deemed to 
be the one resulting in the lowest error values and were 
as follows: Bayesian linear regression for total vitamin 
D, homocysteine and vitamin B12; Random Forrest for 
riboflavin (measured by EGRac); and Bayesian with boot-
strapping for folate. The values obtained were entered 
into the final version of the databank prior to analysis.
Statistical analysis was performed using SPSS v24. 
Intention-to-treat analysis was performed, followed by a 
per-protocol analysis where only data from participants 
who completed the 16-week intervention were included. 
Normality tests were performed, and all non-normally 
distributed data were log-transformed prior to analysis. 
Differences between intervention and placebo group at 
baseline were assessed using independent samples t-tests, 
as well as the difference between centres. A baseline-
adjusted Analysis of Covariance (ANCOVA) model was 
fitted for each outcome with study group as a factor. The 
ANCOVA models for B vitamin biomarkers were then 
further adjusted for baseline homocysteine status.
Results
Monitoring of B vitamin stability in the fortified drinks
Characterisation of the content of the drinks was per-
formed 3 times over the course of 19 months. The active 
drink was identical to placebo in terms of caloric and 
nutrient composition with the exception of B vitamin 
content (Table 1). One month following manufacture all 
four B vitamins were present at the intended concen-
tration. Following a shelf life of 14  months, vitamin B2, 
vitamin B6 and vitamin B12 remained stable. However, a 
decline in folic acid content was detected (90 μg remain-
ing—55% loss of folic acid). Further analysis at 19 months 
post manufacture revealed that folic acid had declined 
further to 56 µg (72% of folic acid lost). At this timepoint 
there was no decline in vitamin B2, B6 or B12 (Table 2).
Supplementation with B vitamin drinks for 16 weeks 
improved B‑vitamin status
A total of 81 participants commenced the study, 37 
completed the active arm and 33 completed the placebo 
arm (Fig.  1). Participants had a mean age of 64.9  years, 
Table 1 Nutritional content (per 200 ml portion) of the placebo 
drinks and active drinks
Nutrients reported as concentration per 200 ml drink; participants received 
1 × 200 ml portion daily
Placebo Active
Energy (kcal) 211 211
Protein (g) 6.4 6.4
Carbohydrate (g) 21.7 21.7
Fat (g) 11 11
Omega 3 (mg) 2400 2400
Vitamin D3 (µg) 10 10
Folic acid (µg) 0 200
Vitamin B12 (µg) 0 10
Vitamin B6 (mg) 0 10
Riboflavin (mg) 0 5
Page 5 of 11Heffernan et al. Nutrition & Metabolism          (2021) 18:104  
and median body mass index (BMI) of 25.4 kg/m2 (IQR 
23.41–29.46). Median riboflavin status (EGRac of 1.31) 
was in the insufficient range, with 54.3% of participants 
having EGRac values indicating riboflavin deficiency or 
insufficiency (EGRac ≥ 1.3). Median homocysteine con-
centrations were relatively high (11.55  nmol/L), with 
59.3% of participants’ homocysteine above the recent 
consensus statement on homocysteine and dementia 
cut-off of 11  nmol/L. All participants had serum vita-
min B6 concentrations above the commonly used cut-
off for deficiency of 20  nmol/L, while a small number 
(4.9%) had serum concentrations considered suboptimal 
(20–30 nmol/L). Most participants had sufficient serum 
Table 2 B vitamin content of the drinks throughout the 
intervention period
B vitamins reported as concentration per 200 ml drink; participants received 
1 × 200 ml portion daily
Time after 
manufacture






1 month 200 10 10 5
14 months 90 12 10 5
19 months 56 15 14 6
Assessed for eligibility (n=300)
Excluded (n= 205)
- Not meeng inclusion criteria (n=146)
- Declined to parcipate (n=12)
- Other reasons (n=47)
Analysed (n=37)
- Excluded from analysis (n=0)
Disconnued intervenon (n=4)
- Dislike of drinks (n=2)
- Other (n=0)
- Unknown (n=2)
Allocated to acve drink (n=46)
- Received allocated intervenon (n=41)
- Did not receive allocated intervention 
(withdrew from study) (n=5)
Disconnued intervenon (n=7)ᶧ
- Dislike of drinks (n=3)
- Other* (n=1)
- Unknown (n=3)
Allocated to placebo (n=49)
- Received allocated intervenon (n=40)
- Did not receive allocated intervenon 
(withdrew from study) (n=9)
Analysed (n=33)






Fig. 1 CONSORT flow diagram for opti-age food intervention study. *Participant discontinued taking the drinks as they travelled abroad frequently 
and were unable to take drinks with them. +One participant who discontinued taking the drinks provided a blood sample at a debriefing 
appointment which was included in the intention-to-treat analysis
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folate (91.4% above World Health Organisation cut-off of 
10 nmol/L) and vitamin B12 (81.5% of participants with 
normal B12 concentrations i.e. above 221 pmol/L) status.
The active and placebo groups were matched in terms 
of anthropometric variables and B vitamin status. Homo-
cysteine concentrations, however, were borderline sig-
nificantly higher at baseline in the intervention group 
compared with the control group (p = 0.047) (Table  3). 
Differences between study centres were also examined, 
with no significant difference in baseline of any of the B 
vitamin biomarkers. UCD participants were significantly 
younger, had lower waist circumference and blood pres-
sure and had significantly higher vitamin D concentra-
tions compared to participants at the UU centre.
Intention to treat (ITT) analysis of the B vitamins 
demonstrated a significant improvement in status of 
all measured B vitamins post intervention in response 
to the fortified drinks. Furthermore, a significant low-
ering of homocysteine concentrations from 11.86 to 
10.56 µmol/L was observed (Table 4). Vitamin D concen-
trations did not differ between the groups following the 
intervention (Table  4). Controlling for baseline homo-
cysteine concentrations did not impact the results except 
for vitamin B6; following inclusion of homocysteine in 
the model the change in vitamin B6 was no longer signifi-
cant (p = 0.075) (Additional file 1: Table S1).
Inclusion of only participants who completed the 
16-week intervention in a per-protocol analysis yielded 
Table 3 Baseline characteristics of treatment groups
Data presented as mean (SD) and median (IQR). P value of differences between treatment groups, p < 0.05 considered statistically significant. BP, blood pressure; 
EGRac, erythrocyte glutathione reductase activation coefficient; PLP, Pyridoxal 5′-phosphate
Demographic variable Group P value
Placebo Active
(n 40) (n 41) –
Age (years) 65.2 (8.4) 64.7 (6.3) 0.784
Sex n male (female) 17 (23) 16 (25) –
Weight (kg) 73.0 (63.4–84.0) 72.8 (63.3–84.2) 0.916
Height (m) 1.69 (0.09) 1.68 (0.08) 0.587
BMI (kg/m2) 25.5 (23.5–29.5) 25.4 (23.4–29.5) 0.860
Waist (cm) 92.70 (82.63–102.50) 89.75 (81.50–105.05) 0.702
Hip (cm) 104.28 (8.56) 104.42 (8.74) 0.944
Waist:hip 0.89 (0.09) 0.90 (0.10) 0.605
Systolic BP (mmHg) 130.9 (19.7) 127.6 (20.3) 0.469
Diastolic BP (mmHg) 76.2 (8.6) 74.6 (10.1) 0.321
Plasma total 25(OH)D (nmol/L) 62.5 (22.4) 59.3 (25.2) 0.539
Serum Homocysteine (µmol/L) 11.05 (9.68–12.75) 11.86 (10.29–15.05) 0.047
Serum folate (nmol/L) 18.0 (14.3–21.9) 15.5 (11.8–21.6) 0.123
Serum vitamin B12 (pmol/L) 336 (235–449) 310 (246–409) 0.357
Plasma PLP (vitamin B6; nmol/L) 61.7 (48.6–85.1) 59.4 (44.5–74.1) 0.487
Riboflavin (EGRac) 1.29 (1.24–1.35) 1.34 (1.25–1.43) 0.168
Table 4 B vitamin biomarkers before and after intervention with a B vitamin-fortified and placebo drink
Data presented as mean (SD) or median (IQR). P value of group effects when analysed by ANCOVA adjusted for baseline values in intention-to-treat analysis. P < 0.05 
considered statistically significant. EGRac, erythrocyte glutathione reductase activation coefficient; PLP, Pyridoxal 5′-phosphate
Placebo Active P value
Pre‑intervention Post‑intervention Pre‑intervention Post‑intervention
Plasma Total 25(OH)D (nmol/L) 62.5 (22.4) 66.9 (17.0) 59.3 (25.20) 65.5 (25.8) 0.727
Serum homocysteine (µmol/L) 11.1 (9.7–12.8) 11.3 (9.9–13.2) 11.9 (10.3–15.1) 10.6 (9.4–13.0) 0.000240
Serum folate (nmol/L) 18.0 (14.3–22.0) 16.6 (13.0–21.8) 15.5 (11.8–21.6) 17.9 (12.7–23.6) 0.000439
Serum vitamin B12 (pmol/L) 336 (235–449) 342 (268–468) 310 (246–409) 428 (307–549) 0.005
Plasma PLP (vitamin B6; (nmol/L) 61.7 (48.6–85.1) 65.4 (38.3–104.9) 59.4 (44.5–74.1) 253.0 (181.0–351.4) 0.002
Riboflavin (EGRac) 1.29 (1.24–1.35) 1.30 (1.23–1.36) 1.34 (1.25–1.43) 1.14 (1.09–1.23) 3.2014 ×  10–9
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similar results. The baseline characteristics were simi-
lar with baseline homocysteine concentrations sig-
nificantly different between the groups (p = 0.035) 
(Table 5). The intervention significantly improved all B 
vitamin biomarkers compared to placebo (Additional 
file 1: Table S2). All changes in the B vitamin remained 
significant following adjustment for baseline homo-
cysteine concentrations (Additional file  1: Table  S3). 
Per-protocol analysis performed for anthropometric 
variables (weight, BMI, systolic and diastolic blood 
pressure) found no significant differences between the 
active and placebo group after the 16-week interven-
tion (Table 6).
Discussion
The results of the 16-week intervention demonstrated 
that the B vitamin-fortified drinks were a successful vehi-
cle for optimising B vitamin status in older adults. Com-
pared with placebo, there was a significant increase in the 
concentration of folate, vitamin B12, vitamin B6 and as 
well as a significant decrease in the related metabolite, 
homocysteine. The four B vitamins included in the for-
tified drinks are involved in one-carbon metabolism and 
it is well established that supplementation with these B 
vitamins can lower homocysteine levels [7].
To our knowledge, there are limited interventions using 
a fortified drink to deliver B vitamin supplementation in 
Table 5 Baseline characteristics of the treatment groups (per-protocol)
Data presented as mean (SD) and median (IQR). Per-protocol analysis includes all participants who completed the 16-week intervention. P value of differences 
between groups, p < 0.05 considered statistically significant. BP, blood pressure; EGRac, erythrocyte glutathione reductase activation coefficient; PLP, Pyridoxal 
5′-phosphate
Baseline characteristic Group P value
Placebo Active
(n 33) (n 37) –
Age (years) 64.6 (8.2) 64.4 (6.0) 0.892
Sex (% female) 54.5 59.5 –
Weight (kg) 72.5 (61.7–80.2) 72.8 (63.3–84.2) 0.881
Height (m) 1.69 (0.10) 1.68 (0.08) 0.535
BMI (kg/m2) 24.8 (23.0–28.3) 25.4 (23.4–29.5) 0.582
Waist (cm) 90.8 (81.5–100.3) 89.8 (81.5–105.1) 0.539
Hip (cm) 102.0 (97.8–107.3) 102.1 (99.6–109.1) 0.844
Waist:hip 0.88 (0.09) 0.90 (0.10) 0.455
Systolic BP (mmHg) 129.2 (20.0) 127.2 (21.1) 0.694
Diastolic BP (mmHg) 76.0 (9.2) 75.2 (11.5) 0.765
Plasma total 25(OH)D (nmol/L) 59.6 (49.3–73.5) 58.8 (37.6–65.4) 0.500
Serum homocysteine (µmol/L) 10.5 (9.6–12.6) 11.6 (10.0–14.8) 0.035
Serum folate (nmol/L) 18.2 (14.1–24.0) 15.5 (12.5–21.6) 0.177
Serum vitamin B12 (pmol/L) 344 (243–439) 310 (246–413) 0.374
Plasma PLP (vitamin B6 (nmol/L) 63.9 (49.1–79.8) 59.4 (45.5–79.4) 0.388
Riboflavin (EGRac) 1.28 (1.22–1.34) 1.34 (1.25–1.41) 0.088
Table 6 Anthropometric and blood pressure before and after a 16-week intervention with B vitamin-fortified drinks (per-protocol 
analysis)
Data presented as mean (SD) and median (IQR). Per-protocol analysis includes participants who completed the 16-week intervention. P value of group effects when 
analysed by ANCOVA adjusted for baseline status. P < 0.05 considered statistically significant. BP, blood pressure
Placebo Active P value
Pre‑intervention Post‑intervention Pre‑intervention Post‑intervention
Weight (kg) 72.5 (61.7–80.2) 74.5 (63.0–83.0) 72.8 (63.3–84.2) 74.4 (64.5–83.8) 0.593
BMI (kg/m2) 24.8 (23.0–28.3) 24.9 (23.6–29.1) 25.4 (23.4–29.5) 25.2 (23.6–29.3) 0.618
Waist circumference (cm) 90.8 (81.5–100.3) 93.0 (82.0–100.0) 89.8 (81.5–105.1) 89.0 (84.5–107.0) 0.967
Systolic BP (mmHg) 129.2 (20.0) 130.9 (16.3) 127.2 (21.1) 127.7 (19.2) 0.516
Diastolic BP (mmHg) 76.0 (9.2) 76.2 (8.6) 75.2 (11.5) 74.6 (10.1) 0.503
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an older population. A previous study delivered multiple 
vitamins, including B vitamins and minerals in a drink 
for 6 months to an older population [29]. Similar results 
to the present study were obtained for vitamin B12 with 
an improvement in concentrations while homocysteine 
concentrations were also significantly decreased. Inter-
estingly the B vitamin content of the drinks were lower 
than our study indicating the effectiveness of low-dose 
B vitamin supplementation. In a second study using the 
same concentrations of B vitamins in fortified drinks as 
the current study, improvements in vitamin B6 and folate 
status after 24  weeks of supplementation was reported 
[20]. Collectively, the results demonstrate the potential 
of fortified drinks as viable options for improvement of 
B vitamin status. Furthermore, the wide age range (51–
84 years) of the participants included support the poten-
tial of such drinks in promoting healthy ageing.
To date the majority of work concerning optimisa-
tion of B vitamin status has focused on the use of cap-
sules in supplementation studies. However, comparing 
the results of our intervention to B vitamin interventions 
using capsules is more difficult as capsule interventions 
are generally of much longer duration and intervene with 
higher amounts of B vitamins. For example, the VITA-
COG study supplemented participants for 2  years with 
800 µg folic acid, 500 µg vitamin B12 and 20 mg vitamin 
B6 daily [27]—4 times the amount of folic acid and 50 
times the amount of vitamin B12 used in the Opti-Age 
Food Intervention Study. As a result, plasma folate con-
centrations increased by 270% and plasma vitamin B12 
doubled in VITACOG participants. In comparison, Opti-
Age participants consuming the active drinks had a mean 
serum folate increase of 16% and a mean serum vitamin 
B12 increase of 41%. Given the shorter intervention and 
much lower amount of vitamin B12 in the drinks com-
pared to the VITACOG supplement, the Opti-Age Food 
Intervention Study was very effective in increasing vita-
min B12 status. The lower percent change in serum folate 
was likely due to the decomposition of folic acid in the 
Opti-Age drinks over time. A supplement in tablet form 
containing 1 mg of vitamin B12 was given to participants 
with vitamin B12 deficiency for 1  year, which caused 
a 177% increase in the vitamin B12 concentrations of 
participants [6]. Here, again, the higher dose and longer 
duration of this study likely accounts for the size of the 
increase in vitamin B12 concentrations. An Australian 
study which provided B vitamin supplementation in the 
form of a multivitamin, mineral and antioxidant tablet 
had an intervention of the same duration as the Opti-
Age Food Intervention Study—16  weeks [10]. This sup-
plement had a men’s and women’s version with the men’s 
version containing 35  mg riboflavin, 25  mg vitamin B6, 
500 µg folic acid and 120 µg vitamin B12 and the women’s 
version containing 30  mg riboflavin, 30  mg vitamin B6, 
500  µg folic acid and 115  µg vitamin B12. However, a 
significant effect of supplementation was only seen for 
vitamin B6 and B12, with no effect on riboflavin or folate 
status. Although comparison of the two methods of sup-
plementation is difficult, and there are many factors that 
may also impact the success of interventions such as the 
baseline B vitamin status, the form of the B vitamins used 
(e.g. folic acid vs methyltetrahydrofolate) and the age 
and health status of the participants, the present results 
indicate that improvements in B vitamin status can be 
achieved using lower concentrations of B vitamins in a 
drink format. Supplementation with lower concentra-
tions of B vitamins may be preferable as an amount more 
in line with daily recommendations and be more readily 
accepted by consumers. In addition, using low-dose sup-
plementation greatly reduces the risk of B vitamin tox-
icity or overconsumption. A Tolerable Upper Limit of 
25 mg/day has been set for vitamin B6 intake in Ireland 
while a limit of 1 mg/day has been adopted for folic acid 
as high intakes have the potential to mask vitamin B12 
deficiency [8]. In the case of vitamin B12, no upper limit 
has been set as bioavailability is low. Although prevalence 
of insufficient levels of B6, B12 and folate were lower 
in our study than previously observed, we found high 
prevalence of insufficiency in riboflavin and higher than 
recommended homocysteine levels, the latter of which 
can be affected by all B vitamins included in the drinks. 
Therefore, the drinks can be useful to optimize B vitamin 
status and associated metabolites in older populations.
Despite a policy of voluntary fortification of foods, it is 
clear from previous evidence that a significant propor-
tion of older adults living in Ireland have sub-optimal B 
vitamin status. It is also evident that the current policy 
of voluntary fortification leaves a significant proportion 
of the population vulnerable to low intakes of B vitamins, 
with results from NANS identifying over 20% of Irish 
adults as being non-consumers of foods fortified with 
folic acid and over 30% as non-consumers of foods forti-
fied with vitamin B12 [12]. In addition to this, only 16% 
of non-consumers of fortified food had optimal red blood 
cell folate status compared with 47% of those classed as 
high consumers of fortified food. In the TUDA cohort, 
red blood cell concentrations of folate significantly 
increased with increasing levels of fortified food con-
sumption [22]. This is consistent with previous evidence 
from Northern Ireland which showed that fortified food 
intake was associated with significantly higher intakes 
and biomarker status of B vitamins [11]. Therefore, forti-
fied foods have an essential role to play in optimising B 
vitamin intakes and biomarkers in older adults.
Within the present work we observed a sharp decline 
in folic acid concentrations following manufacture. The 
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drinks used in our intervention had fruit juice as the 
main ingredient. A previous study examining the decline 
of folic acid content in various fruit juice drinks over time 
found an average 46% decrease in folic acid content by the 
end of the testing period [9]. The drink products tested 
initially contained 90% more folic acid than indicated on 
the label but this had decreased to around, or just below, 
the concentration indicated after 1 year. Therefore, add-
ing more folate can be a strategy to deal with degrada-
tion over time, but large amounts are needed to ensure 
that concentrations are still above the target after long 
term storage. Numerous factors can affect the stability of 
folic acid in drinks, such as the pH of the solution with 
folic acid showing reduced stability at acidic pH values 
[1]. As the pH of the Opti-Age drinks was between 3.5 
and 4, this was most likely a factor contributing to the 
decline in the folic acid concentration. Other factors such 
as light also cause accelerated degradation of folic acid 
[9]; however, the Opti-Age drinks were packed in opaque 
cartons to reduce this impact. Additionally, research has 
shown that small amounts of ethanol, present in added 
flavourings can also attenuate folic acid stability in drinks 
when combined with an acidic pH [14]. Therefore, future 
research into strategies such as encapsulation is needed 
to optimise the incorporation of folic acid into fortified 
fruit drinks [25]. Despite the decline in folic acid content, 
a significant effect of consuming the B vitamin-fortified 
drinks on folate status was observed.
Both the intervention and placebo drinks contained 
10  µg vitamin D per drink. Although there was a sig-
nificant difference in vitamin D status between study 
centres at baseline, there was no difference between the 
intervention and placebo group. Additionally, there was 
no treatment effect of vitamin D, as expected. In general, 
vitamin D status in this population was optimal prior to 
the intervention starting with 70.4% of participants hav-
ing a serum vitamin D concentration of > 50  nmol/L. 
Only 3.7% of participants had a baseline serum vitamin D 
concentration of < 25 nmol/L. However, supplementation 
with vitamin D contained in fortified drinks appeared to 
prevent a trough in vitamin D concentrations that can 
often occur in the winter and spring months at higher 
latitudes [18, 19]. The difference between centres at base-
line can perhaps be explained by the difference in latitude 
between Dublin (UCD) and Coleraine (UU), and also by 
the fact that UCD participants commenced the interven-
tion earlier in the year compared to the UU participants 
(August–October compared to October–December). 
While numerous previous intervention studies have used 
Smartfish drinks containing vitamin D, vitamin D sta-
tus was generally not a primary outcome and pre- and 
post-intervention vitamin D status was not reported [5, 
15, 24]. However, our results clearly show maintenance 
of vitamin D status was achieved over the winter months 
with daily consumption of a drink containing 10  µg of 
vitamin D. The present drinks contain 200 kcal per drink 
and any future use should take suitable steps to substitute 
the drinks for unhealthy snacks or other foods to avoid 
and increase in energy intake.
One limitation of this study was the loss of folic acid 
in the drinks over time following manufacture. There-
fore, although we showed a significant increase in serum 
folate concentrations after 16 weeks of intervention with 
the fortified drink, this response may have been less than 
expected owing to participants receiving less folic acid 
per drink than intended. Likewise, the corresponding 
decrease in homocysteine concentrations as a result of 
intervention may have been lessened. Another limitation 
is that we relied on the participants to self-report their 
compliance and to return any drinks that were not con-
sumed. To combat this an ITT analysis was performed. 
Also, as a result of a higher than expected drop-out rate 
in the placebo group, the total of number of participants 
who completed the trial (i.e. 37 in the active arm and 33 
in the placebo arm) was somewhat less than our sample 
size estimate of 38 subjects required per treatment group. 
However, we do not consider this to be a serious limita-
tion given the current results which, despite the smaller 
participant numbers, showed significant increases in the 
status of all B vitamins, and correspondingly, a decrease 
in the related metabolite homocysteine, after interven-
tion with the fortified drink. The major strength of the 
study is that we used a randomised, double-blinded study 
design, providing cause-and-effect evidence that the 
improvement in B vitamin status shown is owing to the 
B vitamins provided by the fortified drinks, rather than 
any other dietary factors. The addition of vitamin D to 
both the active and placebo drinks was another strength 
of the study, as it benefitted all participants, regardless of 
group assignment and therefore encouraged compliance. 
The statistical approach used is another strength of the 
research. Missing biomarker data were imputed using 
three methods with the most appropriate for each bio-
marker chosen allowing all participants who commenced 
the intervention to be included in analysis with realistic 
post-intervention data.
Conclusions
In conclusion, a B vitamin-fortified drink was effective 
in optimising B vitamin status and was generally well 
received by participants, making this a useful interven-
tion strategy to improve B vitamin status in older adults. 
Further studies should address whether there are longer 
term health benefits for older adults of intervention with 
folate and related B vitamins at these intake levels.
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